Patents by Inventor Edward Clark

Edward Clark has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for antigen targeting to CD180
    Patent number: 12371672
    Abstract: The present invention provides compositions of CD180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.
    Type: Grant
    Filed: May 16, 2024
    Date of Patent: July 29, 2025
    Assignee: UNIVERSITY OF WASHINGTON
    Inventors: Edward Clark, Jay Wesley Chaplin
  • Compositions and Methods for Antigen Targeting to CD180
    Publication number: 20240301364
    Abstract: The present invention provides compositions of CD180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.
    Type: Application
    Filed: May 16, 2024
    Publication date: September 12, 2024
    Inventors: Edward CLARK, Jay Wesley CHAPLIN
  • Compositions and methods for antigen targeting to CD180
    Patent number: 12018291
    Abstract: The present invention provides compositions of CD 180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.
    Type: Grant
    Filed: December 9, 2022
    Date of Patent: June 25, 2024
    Assignee: UNIVERSITY OF WASHINGTON
    Inventors: Edward Clark, Jay Wesley Chaplin
  • Compositions and Methods for Antigen Targeting to CD180
    Publication number: 20230113073
    Abstract: The present invention provides compositions of CD 180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.
    Type: Application
    Filed: December 9, 2022
    Publication date: April 13, 2023
    Inventors: Edward CLARK, Jay Wesley CHAPLIN
  • Compositions and methods for antigen targeting to CD180
    Patent number: 11549102
    Abstract: The present invention provides compositions of CD180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.
    Type: Grant
    Filed: December 31, 2019
    Date of Patent: January 10, 2023
    Assignee: University of Washington
    Inventors: Edward Clark, Jay Wesley Chaplin
  • Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV core antigen
    Patent number: 11324819
    Abstract: Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and/or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: May 10, 2022
    Assignees: University of Washington, Abacus Bioscience, Inc.
    Inventors: Edward Clark, Deborah L. Fuller, Che-Leung Law, Amanda Mak
  • Therapeutic Vaccine for Hepatitis B Virus (HBV) using the HBV Core Antigen
    Publication number: 20200306367
    Abstract: Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and/or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.
    Type: Application
    Filed: November 22, 2016
    Publication date: October 1, 2020
    Inventors: Edward CLARK, Deborah L. FULLER, Che-Leung LAW, Amanda MAK
  • Compositions and Methods for Antigen Targeting to CD180
    Publication number: 20200216819
    Abstract: The present invention provides compositions of CD180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.
    Type: Application
    Filed: December 31, 2019
    Publication date: July 9, 2020
    Inventors: Edward CLARK, Jay Wesley CHAPLIN
  • Compositions and methods for antigen targeting to CD180
    Patent number: 10563179
    Abstract: The present invention provides compositions of CD180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: February 18, 2020
    Assignee: University of Washington Through Its Center for Commercialization
    Inventors: Edward Clark, Jay Wesley Chaplin
  • Compositions and Methods for Antigen Targeting to CD180
    Publication number: 20190144834
    Abstract: The present invention provides compositions of CD180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.
    Type: Application
    Filed: January 11, 2019
    Publication date: May 16, 2019
    Inventors: Edward CLARK, Jay Wesley CHAPLIN
  • Compositions and methods for antigen targeting to CD180
    Patent number: 10196614
    Abstract: The present limiting provides compositions of CD 180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: February 5, 2019
    Assignee: University of Washington Through its Center for Commercialization
    Inventors: Edward Clark, Jay Wesley Chaplin
  • Compositions and Methods for Antigen Targeting to CD180
    Publication number: 20150238630
    Abstract: The present limiting provides compositions of CD 180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.
    Type: Application
    Filed: September 16, 2013
    Publication date: August 27, 2015
    Inventors: Edward Clark, Jay Wesley Chaplin
  • Powder coating extrusion process using liquid
    Patent number: 8377346
    Abstract: A process for the manufacture of a powder coating comprising the steps of: Preparing a powder coating premix comprising a resin and optionally a crosslinker therefor; Feeding the premix through a melt extruder; Cooling the extruded material; and Comminuting it to fine particles, wherein said process is characterized in that between 1 and 25 wt. % (based on the weight of said premix) of a process liquid is added to the melt extruder, wherein said process liquid is immiscible with at least said resin of the powder coating premix and wherein said process liquid evaporates when the premix leaves the extruder.
    Type: Grant
    Filed: September 11, 2008
    Date of Patent: February 19, 2013
    Assignee: Akzo Nobel Coatings International B.V.
    Inventors: Andrew Robert Morgan, Stephen Raymond Wilburn, Edward Clark
  • POWDER COATING EXTRUSION PROCESS USING LIQUID
    Publication number: 20100305268
    Abstract: A process for the manufacture of a powder coating comprising the steps of: Preparing a powder coating premix comprising a resin and optionally a crosslinker therefor; Feeding the premix through a melt extruder; Cooling the extruded material; and Comminuting it to fine particles, wherein said process is characterized in that between 1 and 25 wt. % (based on the weight of said premix) of a process liquid is added to the melt extruder, wherein said process liquid is immiscible with at least said resin of the powder coating premix and wherein said process liquid evaporates when the premix leaves the extruder.
    Type: Application
    Filed: September 11, 2008
    Publication date: December 2, 2010
    Inventors: Andrew Robert Morgan, Stephen Raymond Wilburn, Edward Clark
  • Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
    Patent number: 7833783
    Abstract: The cloning of a novel PCVII viral genome is described as is expression of proteins derived from the PCVII genome. These proteins can be used in vaccine compositions for the prevention and treatment of PCVII infections, as well as in diagnostic methods for determining the presence of PCVII infections in a vertebrate subject. Polynucleotides derived from the viral genome can be used as diagnostic primers and probes.
    Type: Grant
    Filed: July 12, 2006
    Date of Patent: November 16, 2010
    Assignee: Merial SAS
    Inventors: Deborah Haines, Gordon Allan, John Ellis, Brian Meehan, Edward Clark, Lori Hassard, John Harding, Catherine Elisabeth Charreyre, Gilles Emile Chappuis, Francis McNeilly, Li Wang, Lorne A. Babiuk, Andrew A. Potter, Philip Willson
  • Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
    Patent number: 7803926
    Abstract: The cloning of a novel PCVII viral genome is described as is expression of proteins derived from the PCVII genome. These proteins can be used in vaccine compositions for the prevention and treatment of PCVII infections, as well as in diagnostic methods for determining the presence of PCVII infections in a vertebrate subject. Polynucleotides derived from the viral genome can be used as diagnostic primers and probes.
    Type: Grant
    Filed: September 15, 2006
    Date of Patent: September 28, 2010
    Assignee: Merial SAS
    Inventors: Deborah Haines, Gordon Allan, John Ellis, Brian Meehan, Edward Clark, Lori Hassard, John Harding, Catherine Elisabeth Charreyre, Gilles Emile Chappuis, Francis McNeilly, Li Wang, Lorne A. Babiuk, Andrew A. Potter, Philip Willson
  • Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
    Patent number: 7803613
    Abstract: The cloning of a novel PCVII viral genome is described as is expression of proteins derived from the PCVII genome. These proteins can be used in vaccine compositions for the prevention and treatment of PCVII infections, as well as in diagnostic methods for determining the presence of PCVII infections in a vertebrate subject. Polynucleotides derived from the viral genome can be used as diagnostic primers and probes.
    Type: Grant
    Filed: July 12, 2006
    Date of Patent: September 28, 2010
    Assignee: Merial SAS
    Inventors: Deborah Haines, Gordon Allan, John Ellis, Brian Meehan, Edward Clark, Lori Hassard, John Harding, Catherine Elisabeth Charreyre, Gilles Emile Chappuis, Francis McNeilly, Li Wang, Lorne A. Babiuk, Andrew A. Potter, Philip Willson
  • Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
    Patent number: 7504206
    Abstract: The cloning of a novel PCVII viral genome is described as is expression of proteins derived from the PCVII genome. These proteins can be used in vaccine compositions for the prevention and treatment of PCVII infections, as well as in diagnostic methods for determining the presence of PCVII infections in a vertebrate subject. Polynucleotides derived from the viral genome can be used as diagnostic primers and probes.
    Type: Grant
    Filed: September 1, 2005
    Date of Patent: March 17, 2009
    Assignee: Merial SAS
    Inventors: Deborah Haines, Gordon Allan, John Ellis, Brian Meehan, Edward Clark, Lori Hassard, John Harding, Catherine Elisabeth Charreyre, Gilles Emile Chappuis, Francis McNeilly, Li Wang, Lorne A. Babiuk, Andrew A. Potter, Philip Willson
  • Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
    Patent number: 7211379
    Abstract: Provided is a method for reducing viral load of porcine circovirus type 2 (PCV-2) in a pig by inducing an immune response against PCV-2 through the administration of an immunogenic composition comprising a PCV-2 antigen. A preferred antigen is a vector containing a PCV-2 nucleotide sequence. In a particularly preferred embodiment, the PCV-2 nucleotide sequence is ORF4, ORF13, or ORF4 and ORF13. In some embodiments, the immunogenic composition includes one or more additional pig pathogens.
    Type: Grant
    Filed: February 17, 2004
    Date of Patent: May 1, 2007
    Assignee: Merial SAS
    Inventors: John Ellis, Gordon Moore Allan, Brian Meehan, Edward Clark, Deborah Haines, Lori Hassard, John Harding, Catherine Elisabeth Charreyre, Gilles Emile Chappuis, George Steve Krakowka, Jean-Christophe Francis Audonnet, Francis McNeilly
  • Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
    Patent number: 7192594
    Abstract: The cloning of a novel PCVII viral genome is described as is expression of proteins derived from the PCVII genome. These proteins can be used in vaccine compositions for the prevention and treatment of PCVII infections, as well as in diagnostic methods for determining the presence of PCVII infections in a vertebrate subject. Polynucleotides derived from the viral genome can be used as diagnostic primers and probes.
    Type: Grant
    Filed: September 2, 2003
    Date of Patent: March 20, 2007
    Assignees: Merial Limited, Merial SAS
    Inventors: Deborah Haines, Gordon Allan, John Ellis, Brian Meehan, Edward Clark, Lori Hassard, John Harding, Catherine Elisabeth Charreyre, Gilles Emile Chappuis, Francis McNeilly, Li Wang, Lorne A. Babiuk, Andrew A. Potter, Philip Willson